Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Innovent Biologics, Inc.
  6. Summary
    1801   KYG4818G1010

INNOVENT BIOLOGICS, INC.

(1801)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
29.65(c) 27.75(c) 27.75(c) 28.35(c) 27.6(c) Last
13 882 758 35 193 199 26 045 939 10 768 649 16 560 126 Volume
-3.26% -6.41% 0.00% +2.16% -2.65% Change
More quotes
Estimated financial data (e)
Sales 2022 5 038 M 720 M 720 M
Net income 2022 -2 505 M -358 M -358 M
Net cash position 2022 4 717 M 674 M 674 M
P/E ratio 2022 -14,9x
Yield 2022 -
Sales 2023 6 779 M 969 M 969 M
Net income 2023 -1 636 M -234 M -234 M
Net cash position 2023 2 698 M 386 M 386 M
P/E ratio 2023 -22,7x
Yield 2023 -
Capitalization 38 036 M 5 439 M 5 439 M
EV / Sales 2022 6,61x
EV / Sales 2023 5,21x
Nbr of Employees 5 538
Free-Float 92,8%
More Financials
Company
Innovent Biologics, Inc. is a China-based biopharmaceutical company. The CompanyÔÇÖs main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303. 
Sector
Pharmaceuticals
Calendar
03/28Earnings Release
More about the company
Ratings of Innovent Biologics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about INNOVENT BIOLOGICS, INC.
12/05Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phas..
CI
11/14Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Maz..
CI
11/06Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IB..
CI
11/01Innovent Biologics Records $151 Million in Q3 Revenue
MT
10/31Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recomb..
CI
10/17Innovent Announces Phase Ib Results of Higher-Dose Mazdutide in Chinese Participants wi..
CI
10/09China Approves Supplemental New Drug Application for Innovent Biologics' Liver Cancer T..
MT
10/09China Approves Innovent Biologics' New Drug Application for Lung, Thyroid Cancer Medica..
MT
10/09Innovent Biologics, Inc. Announces China NMPA Approves Selpercatinib for the Treatment ..
CI
10/09Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatm..
CI
10/06Hong Kong stocks slip on China concerns after sharp rally
RE
09/07Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, D..
CI
09/05Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of..
CI
08/26Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy
MT
08/25Innovent Biologics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
More news
News in other languages on INNOVENT BIOLOGICS, INC.
12/05Innovent et UNION Therapeutics annoncent le dosage du premier sujet dans une étude clin..
11/14Innovent annonce le dosage du premier participant à une étude clinique de phase 3 (GLOR..
11/06Innovent Biologics, Inc. publie les résultats d'une étude clinique de phase 3 sur le ta..
11/01Innovent Biologics enregistre 151 millions de dollars de recettes au troisième trimestr..
10/31Innovent annonce l'administration d'une dose à un premier patient en Australie dans le ..
More news
Analyst Recommendations on INNOVENT BIOLOGICS, INC.
More recommendations
ETFs positioned on INNOVENT BIOLOGICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Global X MSCI China Health Care ETF - USD3.82%1.52%China
CI Bio-Revolution ETF - CAD2.03%0.95%-NC
Loncar China BioPharma ETF - Distributing - USD1.8%-0.61%China
KraneShares MSCI All China Health Care Inde...1.63%3.08%China
KraneShares Emerging Market Healthcare Inde...0.6%1.00%NC
More ETFs positioned on INNOVENT BIOLOGICS, INC.
Chart INNOVENT BIOLOGICS, INC.
Duration : Period :
Innovent Biologics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNOVENT BIOLOGICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 24,82 CNY
Average target price 42,31 CNY
Spread / Average Target 70,5%
EPS Revisions
Managers and Directors
De Chao Yu Chairman & Chief Executive Officer
Yong-Jun Liu President
Hao Xi Ede Chief Financial Officer & Executive Director
Jessie Chen Chief Medical Officer
Qin Wei Zhou Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
INNOVENT BIOLOGICS, INC.-41.24%5 587
CSL LIMITED3.46%97 405
SAMSUNG BIOLOGICS CO.,LTD.-7.20%45 203
BIOGEN INC.22.02%41 972
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 815
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.21%19 611